ImmunityBio, Inc. IBRX Change in fair value of derivative liabilities
Change in fair value of derivative liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ChangeInFairValueOfDerivativeLiabilities.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s change in fair value of derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s change in fair value of derivative liabilities?
- ImmunityBio, Inc. (IBRX) reported change in fair value of derivative liabilities of -$1.11M in Q1 2026.
- How has ImmunityBio, Inc.'s change in fair value of derivative liabilities changed year-over-year?
- ImmunityBio, Inc.'s change in fair value of derivative liabilities increased by 80.1% year-over-year, from -$5.58M to -$1.11M.
- What does change in fair value of derivative liabilities mean?
- Non-cash gains or losses resulting from changes in the market value of derivative liabilities.
- How do you interpret change in fair value of derivative liabilities?
- Positive adjustments (gains) reduce net loss, while negative adjustments (losses) increase it, reflecting market-driven valuation shifts rather than operational performance.
- How does change in fair value of derivative liabilities compare across companies?
- Common for companies with complex capital structures or warrants issued as part of financing rounds.